Cubist Pharmaceuticals Inc (CBST.OQ)

CBST.OQ on NASDAQ Stock Exchange Global Select Market

98.67USD
19 Dec 2014
Price Change (% chg)

$0.90 (+0.92%)
Prev Close
$97.77
Open
$98.75
Day's High
$99.25
Day's Low
$98.56
Volume
977,732
Avg. Vol
504,877
52-wk High
$100.98
52-wk Low
$58.52

CBST.OQ

Chart for CBST.OQ

About

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed... (more)

Overall

Beta: 0.70
Market Cap (Mil.): $7,528.06
Shares Outstanding (Mil.): 76.30
Dividend: --
Yield (%): --

Financials

  CBST.OQ Industry Sector
P/E (TTM): 121.55 37.83 38.47
EPS (TTM): 0.81 -- --
ROI: 2.34 18.99 18.25
ROE: 4.47 19.75 19.13
Search Stocks

FDA approves Cubists' drug for antibiotic-resistant bacteria

- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs.

19 Dec 2014

FDA approves Cubists' drug for antibiotic-resistant bacteria

Dec 19 - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs.

19 Dec 2014

TRLPC: Merck looks for $8B bridge for Cubist acquisition

NEW YORK, Dec 15 - Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC.

15 Dec 2014

RPT-Cubist sales force seen as potential boon for Merck intestinal drug

Dec 9 - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.

10 Dec 2014

Cubist sales force seen as potential boon for Merck intestinal drug

- In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.

09 Dec 2014

Cubist sales force seen as potential boon for Merck intestinal drug

Dec 9 - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.

09 Dec 2014

Merck says still plans to buy Cubist, despite patent setback

- Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.

09 Dec 2014

Merck says still plans to buy Cubist, despite patent setback

- Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.

09 Dec 2014

UPDATE 2-Merck says still plans to buy Cubist, despite patent setback

Dec 9 - Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.

09 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds Merck, AAR Corp, Entergy, Santander, Spirit Aerosystems)

09 Dec 2014

Earnings vs. Estimates

Search Stocks